Skip to search formSkip to main contentSkip to account menu

Abnormality of extrapyramidal motor function

Known as: Extrapyramidal symptoms, Extrapyramidal dysfunction, extrapyramidal symptom 
A neurological condition related to lesions of the basal ganglia leading to typical abnormalities including akinesia (inability to initiate changes… 
National Institutes of Health

Related topics

Related topics

35 relations
3-METHYLGLUTACONIC ACIDURIA WITH CATARACTS, NEUROLOGIC INVOLVEMENT, AND NEUTROPENIA3-METHYLGLUTACONIC ACIDURIA WITH DEAFNESS, ENCEPHALOPATHY, AND LEIGH-LIKE SYNDROME3-Methylglutaconic aciduria type 36-pyruvoyl-tetrahydropterin synthase deficiency

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Role of manganese in neurodegenerative diseases.
Review
2008
Review
2008
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Atypical antipsychotic drugs offer several notable benefits over typical antipsychotics, including greater improvement in… 
Highly Cited
2005
Highly Cited
2005
A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder.
OBJECTIVE To evaluate the efficacy and tolerability of quetiapine monotherapy versus placebo for the treatment of mania… 
Review
2004
Review
2004
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
UNLABELLED Aripiprazole, a quinolinone derivative, is an atypical antipsychotic drug indicated for the treatment of adult… 
Highly Cited
2003
Highly Cited
2003
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
BACKGROUND Aripiprazole is a dopamine D2 receptor partial agonist with partial agonist activity at serotonin 5HT1A receptors and… 
Highly Cited
2002
Highly Cited
2002
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
BACKGROUND Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile. The… 
Highly Cited
2002
Highly Cited
2002
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
OBJECTIVE The short-term efficacy and safety of risperidone in the treatment of disruptive behaviors was examined in a well… 
Highly Cited
2000
Highly Cited
2000
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.
BACKGROUND We compared the efficacy and safety of olanzapine vs placebo for the treatment of acute bipolar mania. METHODS Four… 
Highly Cited
1997
Highly Cited
1997
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
OBJECTIVE This international, multicenter double-blind trial was designed to compare the therapeutic profile of an atypical… 
Highly Cited
1997
Highly Cited
1997
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
OBJECTIVE This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License